AB0952 Characterization of patients with psoriatic arthritis in dermatologic and rheumatologic care: an analysis of two disease registries
Authors: L. Lindner, M. Augustin, L. Kühl, A. Weiß, S. J. Rustenbach, F. Behrens, M. Feuchtenberger, I. Schwarze, U. Mrowietz, D. Thaçi, K. Reich, A. Strangfeld, A. Regierer
Journal: Annals of the Rheumatic Diseases (2022)

Background Psoriatic arthritis (PsA) is a chronic inflammatory disease affecting the musculoskeletal system, skin and nails. Therapeutic management in Germany is usually provided by a dermatologist or rheumatologist. Objectives The aim is to characterize the socioeconomic and clinical patient profiles in dermatologic and rheumatologic settings. Methods Baseline data of patients with PsA from [1] the dermatological German Psoriasis Registry PsoBest (PB) and [2] the rheumatological German disease register RABBIT-SpA (RS) [2] were analyzed. For this purpose, comparable anamnestic and clinical variables collected in the period 10/2017 to 12/2020 were identified and descriptively analyzed. The analysis was carried out in each of the data-holding registers. Results 1066 RS patients and 704 PB patients were included in the analysis (Table 1). The proportion of women was higher in the rheumatology setting (RS) (60% vs. 49%). Disease duration of psoriasis was longer in the dermatology setting (PB). Cutaneous severity was higher in PB, including affected body surface area and nail psoriasis. However, more patients in RS had tender joints and swollen joints. The physician-reported global disease activity was higher in RS. The mean DLQI (Dermatology Life Quality Index) was higher in PB and the mean HAQ (Health Assessment Questionnaire) was higher in RS. Patient reported global disease activity and pain were lower in PB. Table 1. Baseline data of patients with PsA from the registers PsoBest and RABBIT-SpA included 10/2017 to 12/2020. RABBIT-SpA(Rheumatology setting) PsoBest(Dermatology setting) N 1066 704 Age, mean (SD) 51.9 (12.2) 51.7 (13.2) Female, n (%) 637 (60) 346 (49) Disease duration skin, mean (SD) 14.3 (13.9) 21.6 (16.0) Body surface area, mean (SD) 8.5 (15.0) 20.8 (19.8) Nail psoriasis, n (%) 434 (41) 407 (58) Tender joints, n (%) 905 (85) 498 (71) Swollen joints, n (%) 708 (67) 387 (55) Physician reported disease activity, mean (SD) 5.2 (1.9) 4.6 (2.7) DLQI, mean (SD) 5.6 (6.2) 12.2 (7.6) HAQ, mean (SD) 0.9 (0.7) 0.7 (0.6) Patient reported disease activity, mean (SD) 5.7 (2.4) 4.9 (2.9) Patient reported pain, mean (SD) 5.5 (2.4) 5.2 (2.8) bDMARD, n (%) 751 (71) 514 (73) TNF, n (%) 346 (46) 117 (23) IL17, n (%) 351 (47) 246 (48) IL23, n (%) 54 (7) 151 (29) tsDMARD, n (%) 109 (10) 47 (7) csDMARD, n (%) 195 (18) 142 (20) Most of the patients received biologics at inclusion (RS: 71% and PB: 73%). In the dermatology setting IL23 inhibitors were used more frequently, whereas TNF inhibitors were used more frequently in the rheumatology setting. Conclusion The clinical specialization of the treating physician was associated with a different treatment and clinical status of patients with PsA. Our analysis showed that patients in the rheumatology setting more frequently had joint affections and lower functional status, whereas skin severity was worse in the dermatology setting, indicating selection effects of health care access. We hypothesize out that these differences may be biased due to different diagnostic and therapeutic routines in the specialized health care settings. Psoriatic arthritis should be treated in a multidisciplinary approach to take into account all facets of this complex disease. References [1]PMID: 24393314 [2]PMID: 30874933 Disclosure of Interests Lisa Lindner Grant/research support from: RABBIT-SpA is supported by a joint, unconditional grant from AbbVie, Amgen, Biogen, Hexal, Janssen-Cilag, Lilly, MSD, Novartis, Pfizer, UCB and Viatris., Matthias Augustin Grant/research support from: The PsoBest registry is/was supported by AbbVie, Almirall Hermal, Amgen, Biogen, BMS, Celgene, Hexal, Janssen-Cilag, LEO Pharma, Eli Lilly, Medac, Novartis, Pfizer, UCB and Viatris. These companies do not have influence on the design of the registry, data collection, analyses, the publication decisions or development., Laura Kühl Grant/research support from: The PsoBest registry is/was supported by AbbVie, Almirall Hermal, Amgen, Biogen, BMS, Celgene, Hexal, Janssen-Cilag, LEO Pharma, Eli Lilly, Medac, Novartis, Pfizer, UCB and Viatris. These companies do not have influence on the design of the registry, data collection, analyses, the publication decisions or development., Anja Weiß Grant/research support from: RABBIT-SpA is supported by a joint, unconditional grant from AbbVie, Amgen, Biogen, Hexal, Janssen-Cilag, Lilly, MSD, Novartis, Pfizer, UCB and Viatris., Stephan Jeff Rustenbach Grant/research support from: The PsoBest registry is/was supported by AbbVie, Almirall Hermal, Amgen, Biogen, BMS, Celgene, Hexal, Janssen-Cilag, LEO Pharma, Eli Lilly, Medac, Novartis, Pfizer, UCB and Viatris. These companies do not have influence on the design of the registry, data collection, analyses, the publication decisions or development., Frank Behrens: None declared, Martin Feuchtenberger: None declared, Ilka Schwarze: None declared, Ulrich Mrowietz: None declared, Diamant Thaçi: None declared, Kristian Reich Grant/research support from: The PsoBest registry is/was supported by AbbVie, Almirall Hermal, Amgen, Biogen, BMS, Celgene, Hexal, Janssen-Cilag, LEO Pharma, Eli Lilly, Medac, Novartis, Pfizer, UCB and Viatris. These companies do not have influence on the design of the registry, data collection, analyses, the publication decisions or development., Anja Strangfeld Grant/research support from: RABBIT-SpA is supported by a joint, unconditional grant from AbbVie, Amgen, Biogen, Hexal, Janssen-Cilag, Lilly, MSD, Novartis, Pfizer, UCB and Viatris., Anne Regierer Grant/research support from: RABBIT-SpA is supported by a joint, unconditional grant from AbbVie, Amgen, Biogen, Hexal, Janssen-Cilag, Lilly, MSD, Novartis, Pfizer, UCB and Viatris.